Published in Cancer Law Weekly, April 8th, 2006
According to a recently published article, scientists in Switzerland conducted a study "to assess the feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated RT."
"Thirty-three consecutive patients [were studied] (male-female ratio, 4.5; median age, 54 years [age range, 39-76 years])," explained M. Ozsahin and colleagues, Centre Hospitalier de l'Universite de Vaudois. "Between November 2000 and January 2003, the 33 patients were treated with curative...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.